SP600125

Synonyms: Nsc75890

SP600125 (Nsc75890) is a broad-spectrum JNK inhibitor for JNK1, JNK2 and JNK3 with IC50 of 40 nM, 40 nM and 90 nM in cell-free assays, respectively; 10-fold greater selectivity against MKK4, 25-fold greater selectivity against MKK3, MKK6, PKB, and PKCα, and 100-fold selectivity against ERK2, p38, Chk1, EGFR etc. SP600125 is also a broad‐spectrum inhibitor of serine/threonine kinases including Aurora kinase AFLT3 and TRKA with of IC50 of 60 nM, 90 nM and 70 nM. SP600125 inhibits autophagy and activates apoptosis.

SP600125 Chemical Structure

SP600125 Chemical Structure

CAS: 129-56-6

Selleck's SP600125 has been cited by 981 publications

Purity & Quality Control

Batch: Purity: 99.94%
99.94

Products often used together with SP600125

Adezmapimod (SB203580)


SP600125 inhibits autophagy and activates apoptosis whereas, Adezmapimod induces mitophagy and autophagy.

PD98059


SP600125 and PD98059 are two kinases that possess pro-survival activities in TQ-induced cell death.

El-Najjar N, et al. Apoptosis. 2010 Feb;15(2):183-95.

SCH772984


SP600125 and SCH772984 significantly increase apoptosis of both PMN-MDSCs and M-MDSCs in vitro.

Yu J, et al. Front Oncol. 2021 Mar 18;11:647312.

LY294002


SP600125 and LY294002 suppress cell growth of SNU-216 and NCI-N87 cells.

Choi Y, et al. World J Gastroenterol. 2016 Nov 7; 22(41): 9141–9153.

Bentamapimod (AS602801)


SP600125 and Bentamapimod are pan-JNK inhibitors that cause a robust reduction in cell viability in a panel of GBM stem cells (GSCs) cultures.

MacLeod G, et al. Cell Rep. 2019 Apr 16;27(3):971-986.e9.

SP600125 Related Products

Signaling Pathway

Choose Selective JNK Inhibitors

Cell Data

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Hep3B Function Assay 10 μM 1 h Blocks autophagy and upregulation of Beclin 1 expression induced by ceramide 19060920
BV-2 Function Assay 2 μM 1 h Inhibits the increase of sBAFF release in Gmix-treated BV-2 cells 19406831
RAW264.7 Function Assay 10 μM 12 h Antiinflammatory activity assessed as inhibition of LPS-induced NO production with IC50 of 17μM 19497418
PC3 Function Assay 20 μM 1 h Decreases the MMP2 and MMP9 expression 19633975
Plasmodium falciparum HB3 Antibacterial Assay 72 h DMSO Antiplasmodial activity with IC50 of 7.94328 μM 19734910
Plasmodium falciparum W2 Antibacterial Assay 72 h DMSO Antiplasmodial activity with IC50 of 7.94328 μM 19734910
Plasmodium falciparum 7G8 Antibacterial Assay 72 h DMSO Antiplasmodial activity with IC50 of 10 μM 19734910
Plasmodium falciparum 3D7 Antibacterial Assay 72 h DMSO Antiplasmodial activity with IC50 of 12.5893 μM 19734910
Plasmodium falciparum GB4 Antibacterial Assay 72 h DMSO Antiplasmodial activity with IC50 of 12.5893μM 19734910
HaCaT Function Assay 20 μM 4 h DMSO Blocks the TNF-α-induced CYP4F11 transcription 19812349
HaCaT Function Assay 20 μM 24 h DMSO Blocks the phosphorylation of c-Jun protein 19812349
A549 Function Assay 20 μM 1 h Inhibition of TPA-induced MMP-2 and u-PA expression 20492175
PC12 Function Assay 10 μM 5 h DMSO Activation of Nrf2/ARE assessed as HO-1 protein induction pretreated with PD98059 21345685
PC12 Function Assay 10 μM 5 h DMSO Activation of Nrf2/ARE assessed as HO-1 protein induction pretreated with U0126 21345685
PC12 Function Assay 10 μM 5 h DMSO Activation of Nrf2/ARE assessed as HO-1 protein induction pretreated with SP600125 21345685
PC12 Function Assay 10 μM 5 h DMSO Activation of Nrf2/ARE assessed as HO-1 protein induction pretreated with SB203580 21345685
B16-F10 Function Assay 1 h Inhibition of TNF-alpha-induced c-JUN phosphorylation 21815634
LoVo Function Assay 1 μM 1 h Inhibition of PGE2-induced expression of uPA and MMP-9 significantly 21859479
LoVo Function Assay 1 μM 1 h BlocksPGE2-induced cell migration significantly 21859479
THP-1 Function Assay 90 nM 30 min Inhibition of tissue factor expression 22940059
PC3 Function Assay 25 μM 24 h Inhibition of AP-1 and p21 luciferase activity induced by S179D PRL 23162652
SH-SY5Y Function Assay 10 μM 1 h DMSO Neuroprotective activity assessed as reduction of anisomycin-induced cell death 23498914
SH-SY5Y Kinase Assay 10 μM 1 h DMSO Inhibition of JNK3 assessed as blockade of anisomycin-induced c-jun phosphorylation at ser73 23498914
RAW264.7 Function Assay 10 μM 24 h Antiinflammatory activity assessed as inhibition of IL-1beta release 23791078
RAW264.7 Function Assay 10 μM 24 h Antiinflammatory activity assessed as inhibition of LPS-induced iNOS expression 23791078
RAW264.7 Function Assay 10 μM 2 h Antiinflammatory activity assessed as inhibition of LPS-induced NO production 23791078
A549 Growth Inhibition Assay 20 μM 72 h DMSO Rapid and potent inhibition of cell proliferation 23912840
RAW264.7 Antiinflammatory assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production relative to control, IC50 = 17 μM. 22831798
BMMC Function assay 1 to 20 uM 7 days Inhibition of RANKL/M-CSF-stimulated osteoclastogenesis in ICR mouse BMMC assessed as reduction in TRAP positive multinucleated cells at 1 to 20 uM incubated for 7 days by light microscopy 25397676
A673 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells 29435139
BT-37 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells 29435139
SK-N-SH qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells 29435139
NB1643 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells 29435139
OHS-50 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells 29435139
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells 29435139
NB-EBc1 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells 29435139
LAN-5 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells 29435139
Click to View More Cell Line Experimental Data

Biological Activity

Description SP600125 (Nsc75890) is a broad-spectrum JNK inhibitor for JNK1, JNK2 and JNK3 with IC50 of 40 nM, 40 nM and 90 nM in cell-free assays, respectively; 10-fold greater selectivity against MKK4, 25-fold greater selectivity against MKK3, MKK6, PKB, and PKCα, and 100-fold selectivity against ERK2, p38, Chk1, EGFR etc. SP600125 is also a broad‐spectrum inhibitor of serine/threonine kinases including Aurora kinase AFLT3 and TRKA with of IC50 of 60 nM, 90 nM and 70 nM. SP600125 inhibits autophagy and activates apoptosis.
Targets
serine/threonine kinase [1] JNK1 [1]
(Cell-free assay)
JNK2 [1]
(Cell-free assay)
Aurora A [4]
(Cell-free assay)
TrkA [4]
(Cell-free assay)
Click to View More Targets
40 nM 40 nM 60 nM 70 nM
In vitro
In vitro

SP600125 is originally characterized as a selective ATP-competitive inhibitor of c-Jun N-terminal kinase JNK. In Jurkat T cells, SP600125 inhibits the phosphorylation of c-Jun with IC50 of 5 μM to 10 μM. In CD4+ cells, such as Th0 cells isolated from either human cord or peripheral blood, SP600125 blocks cell activation and differentiation and inhibits the expression of inflammatory genes COX-2, IL-2, IL-10, IFN-γ, and TNF-α, with IC50 of 5 μM to 12 μM. [1] However, later studies reveal that SP600125 also suppresses aryl hydrocarbon receptor (AhR) [2], Mps1 [3], and a panel of other serine/threonine kinases, including Aurora kinase A, FLT3, MELK, and TRKA [4]. In a mouse beta cells MIN6, SP600125 (20 μM) induces the phosphorylation of p38 MAPK and its downstream CREB-dependent promoter activation. [5] In HCT116 cells, SP600125 (20 μM) blocks the G2 phase to mitosis transition and induces endoreplication. This ability of SP600125 is independent of JNK inhibition, but due to its inhibition of CDK1-cyclin B activation upstream of Aurora A and Polo-like kinase 1. [6]

Kinase Assay In Vitro Kinase Assays
The potency of SP600125 towards kinases, including MPS1, JNK, and Aurora kinase A, is determined based on the specific measurement of radioactive phosphotransfer to the substrate. For each enzyme, the absolute Km values for ATP and the specific substrate are initially determined and each assay is then run at optimized [ATP] (2·αKm) and [substrate] (5·Km) concentrations. MPS1 activity is measured using 5 nM of MPS1 recombinant protein in 50 mM HEPES pH 7.5, 2.5 mM MgCl2, 1 mM MnCl2, 1 mM DTT, 3 μM NaVO3, 2 mM β-glycerophosphate, 0.2 mg/mL BSA, 200 μM P38-βtide substrate-peptide (KRQADEEMTGYVATRWYRAE), and 8 μM ATP with 1.5 nM 33P-γ-ATP. Ten serial 1:3 dilutions (from 30 μM to 1.5 nM) of SP600125 are tested and IC50 determined.
Cell Research Cell lines HCT116, A2780, and U2OS cells
Concentrations 0–5 μM
Incubation Time 72 hours
Method

Cells are seeded in 384 well-plates. One day after seeding, the cells are treated with SP600125 for 72 hours and the plates are then processed using a CellTiter-Glo assay. Inhibitory activity is evaluated comparing treated versus control data and IC50 value of proliferation is calculated.

Experimental Result Images Methods Biomarkers Images PMID
Western blot p-JNK p-IGF1R / IGF1R / p-Akt / Akt / p-ERK / ERK p-Src / Src p-c-Jun / c-Jun / pJNK / JNK Survivin / Bcl-2 / PARP p-FADD / FADD / p-c-Jun / c-Jun 25226534
Immunofluorescence AIF / Endo G E-cadherin / β-catenin α-catenin / Actin 21738692
Growth inhibition assay Cell viability (U-87 MG) Cell viability (A549) 27176481
In Vivo
In vivo

In mice, SP600125 (15 mg/kg or 30 mg/kg) significantly inhibits lipopolysaccharide (LPS)-induced TNF-α expression and anti-CD3-induced apoptosis of CD4+ CD8+ thymocytes. [1]

Animal Research Animal Models Mouse LPS/TNF model (female CD-1)
Dosages 15 or 30 mg/kg
Administration Administered via intravenous injection or orally

Chemical Information & Solubility

Molecular Weight 220.23 Formula

C14H8N2O

CAS No. 129-56-6 SDF Download SP600125 SDF
Smiles C1=CC=C2C(=C1)C3=NNC4=CC=CC(=C43)C2=O
Storage (From the date of receipt)

In vitro
Batch:

DMSO : 44 mg/mL ( (199.79 mM); Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : Insoluble

Ethanol : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
how to reconstitute the inhibitor for in vivo studies?

Answer:
S1460 can be dissolved in 5% DMSO/corn oil at 5 mg/ml as a clear solution for injection. The inhibitor dissolved in vehicle 30% PEG400/0.5% Tween80/5%Propylene glycol, at 30mg/ml is a suspension and can be used for oral administration.

Tags: buy SP600125 | SP600125 supplier | purchase SP600125 | SP600125 cost | SP600125 manufacturer | order SP600125 | SP600125 distributor